ClinicalTrials.gg
RecruitingNCT07241767Updated Apr 8, 2026

A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer

A Phase 2 interventional study of FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin and FH-006 ; SHR-1316 ; BP102 in Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 844 studies in Lung Neoplasms with a site in China — 371 open to participants now, 418 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
146th of 585
200 · median 90
Started
2025
with 105 others
Phase 2
151 of 844
73 open now
Primary completion
2027-11
later than 293 of 417 live
Registered
713th of 844
by date

Among the 844 studies in Lung Neoplasms with a site in China, this one is the 146th largest by planned enrollment of the 585 interventional ones that give a count, is one of 106 that started in 2025, is one of 151 in phase 2, reaches primary completion later than 293 of the 417 other live ones, and was the 713th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

371 of the 844 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

366 more — sign in →

All 371 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 844 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range: 18-75 years old (including both ends), gender is not limited.
  2. Subjects with locally advanced or non-small cell lung cancer confirmed by histology or cytology as unsuitable for radical surgery or radiotherapy treatment
  3. score is 0 or 1
  4. Expected survival period ≥ 12 weeks
  5. According to the v1.1 standard, there must be at least one .
  6. Good level of organ function
  7. The patient voluntarily joined this study and signed
  8. (LVEF) ≥ 50%

Exclusion criteria

Exclusion Criteria:

  1. Suffering from other malignant tumors within the past 5 years
  2. Subjects with active central nervous system (CNS) tumor , a history of meningeal metastasis, or current meningeal metastasis
  3. Patients with uncontrollable tumor related pain
  4. Has serious cardiovascular and cerebrovascular diseases
  5. Significant bleeding symptoms occurred within 3 months prior to the first study medication
  6. Uncontrollable third interstitial fluid accumulation within 2 weeks of initial study medication
  7. History of clinically significant pulmonary diseases
  8. Receive other anti-tumor treatments within 4 weeks before the first medication
  9. Severe infection within 4 weeks before the first medication
  10. Active, known or suspected diseases, and a history of autoimmune diseases.
  11. History of immunodeficiency
  12. Individuals with active pulmonary tuberculosis infection within the year prior to enrollment
  13. Chest radiation therapy patients who received>30 Gy within 24 weeks prior to the first use of the drug
  14. The adverse reactions of previous anti-tumor treatments have not yet recovered to ≤ Grade I
  15. Surgical treatment of important organs within 4 weeks prior to the first use of medication
  16. Use attenuated within 28 days prior to the first use of the investigational drug
  17. There are other serious physical or mental illnesses or laboratory abnormalities present
  18. Pregnant, lactating women, or female participants who plan to become pregnant within 14 months after the last use of the investigational drug during the study period
  19. Having bleeding tendency, high risk of bleeding, coagulation dysfunction or thrombophilia tendency
  20. Previously experienced hypertensive crisis or hypertensive encephalopathy
  21. Suffering from significant vascular disease within 6 months prior to the first use of medication
  22. Have undergone a or other minor surgery within 7 days prior to the first use of medication
  23. Having severe, unhealed wounds, active ulcers, or untreated fractures
  24. Gastrointestinal perforation occurred within 6 months prior to the first use of medication
  25. 24-hour proteinuria quantification ≥ 1g within 7 days before the first medication
  26. CT/MRI indicates tumor surrounding or invading large blood vessels
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Part A

    Drug: FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin

  • Experimental
    Part B

    Drug: FH-006 ; SHR-1316 ; BP102

  • Experimental
    Part C

    Drug: FH-006; SHR-1316 ; SHR-8068

Interventions

06

What researchers measure

Primary outcomes

  1. DLT (Dose-limiting toxicity):Severe toxicity occurred 21 or 28 days after each subject received their first systemic anticancer treatment.

    Time frame: 21or28 days after the first administration of each subject

  2. Incidence of Treatment-Emergent Adverse Events

    Time frame: from first dose to disease progression or death, up to 3 years.

  3. RP2D (Recommended Phase II Dose):This was determined through a comprehensive evaluation of safety data and pharmacokinetic characteristics.

    This was determined through a comprehensive evaluation of safety data and pharmacokinetic characteristics.

    Time frame: from first dose to disease progression or death, up to 3 years

  4. ORR (Objective Response Rate)

    The proportion of patients whose tumor volume shrank to the pre-defined standard (complete or partial response) after treatment.

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

Secondary outcomes

  1. Duration of response (DoR)

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

  2. disease control rate (DCR)

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

  3. progression free survival (PFS)

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

  4. overall survival (OS)

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 21, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2028
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07241767
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Nov 12, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Apr 8, 2026

Study contacts

Xiaouxe Pi
Contact
Xiaoxue.pi@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BP102 · FH-006 · Adebrelimab · Anti-CTLA-4 Monoclonal Antibody SHR-8068

Start the discussion